Research being done over need of booster dose against Covid: AIIMS doctor

Research is taking place in India, US and several other countries to see if booster dose will be needed for maintaining longer efficacy of Covid-19 vaccines

Vaccine
ANI
2 min read Last Updated : Jun 15 2021 | 7:18 AM IST

 

New Delhi [India], June 15 (ANI): Research is taking place in India, US and several other countries to see if booster dose will be needed for maintaining longer efficacy of COVID-19 vaccines, a senior doctor has said.

"It is about five months since the start of vaccination in India. Everyone is looking towards the government, doctors and scientists if they are safe or they need booster dose to make themselves safe. This is the important question and we are having lots of research in India and abroad including US and European countries," Dr Sanjeev Sinha, Professor in Department of Medicine at AIIMS Delhi told ANI.

"We will have other data also in two-three months. Then we will be able to decide on booster dose. Everything will be based on research. There is some work is going on booster dose at AIIMS also," he added.

Dr Sinha said that three vaccines - Covishield , Covaxin and Sputnik V- have been authorised for use in the country against COVID-19.

He said the government took decision to increase the gap between two doses of Covishield after a study was published in a leading medical journal.

Dr Sinha urged people to continue exercising caution against COVID-19 and not get complacent as number of new cases have come down.

"This is a very crucial time. One has to be very careful. People should follow COVID-appropriate behavior and should only come out of their homes when absolutely necessary. It is preferable if people can work from home. If it is mandatory (to go to office), then avoid taking lunch together," he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusAIIMSCoronavirus Vaccine

First Published: Jun 15 2021 | 7:18 AM IST

Next Story